Clinical evaluation of novel markers in the diagnosis of anemia.

Completed

• Conditions: anemia; iron-deficiency; 10002086

• Registration Number: NL-OMON41145
• Lead Sponsor: Catharina-ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

referral by general practitioner (or other specialist) for analysis of anemia
referral by general practitioner (or other specialist) for analysis of exhaustion
age 18 or above

Exclusion Criteria

Age below 18

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Time from baseline until first classification of anemia (iron-deficiency,<br /><br>anemia of chronic disease, other)<br /><br>- Time from baseline until definitive diagnosis (stomach ulcer, colon<br /><br>carcinoma, kidney failure, hematologic malignancy etc.)<br /><br>- Time from baseline until start of therapy if applicable (f.e. iron suppletion)<br /><br>- Therapy response: absolute Hb-increase 8 and 16 weeks from baseline<br /><br>- Therapy response: percentage of required Hb-increase compared to baseline<br /><br>- Therapy response: Delta values of anemia markers (MCV, ferritine, RET-HE,<br /><br>sTfR, sTfR/log(ferritin), Reticulocytes, RPI, transferrin/log(ferritin)) at 16<br /><br>weeks from baseline.<br /><br>- Percentage of patients with normalization of Hb-lever at 16 weeks from<br /><br>baseline (Hb>7.5 and >8.5 mmol/L for women and men respectively)<br /><br>- Shifts in the Thomas plat subsequent to therapy</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable </p><br>